Cheng Su

Cheng Su

Auto-generated profile, based on publicly available information

Cheng Su

Department of Pathology, Duke University School of Medicine, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
JYJianpeng Yu
Jianpeng Yu
CJChen Jin
Chen Jin
CSCheng Su
Cheng Su
DMDavid Moon
David Moon
MSMichael A Sun
Michael A Sun
JHJiaoti Huang
Jiaoti Huang
Purpose: Purine metabolism is a promising therapeutic target in cancer; however, how cancer cells respond to purine shortage, particularly their adaptation and vulnerabilities, remains unclear. Experimental Design: Using the recently developed purine shortage–inducing prodrug DRP-104 and genetic approaches, we investigated the responses in prostate, lung, and glioma cancer models. Results: We demonstrate that when de novo purine biosynthesis is compromised, cancer cells employ microtubules to assemble purinosomes, multiprotein complexes of de novo purine biosynthesis enzymes that enhance purine biosynthesis efficiency. Although this process enables tumor cells to adapt to purine shortage stress, it also renders them more susceptible to the microtubule-stabilizing chemotherapeutic drug docetaxel. Furthermore, we show that although cancer cells primarily rely on de novo purine biosynthesis, they also exploit methylthioadenosine phosphorylase (MTAP)–mediated purine salvage as a crucial alternative source of purine supply, especially under purine shortage stress. In support of this finding, combining DRP-104 with an MTAP inhibitor significantly enhances tumor suppression in prostate cancer models in vivo. Finally, despite the resilience of the purine supply machinery, purine shortage–stressed tumor cells exhibit increased DNA damage and activation of the cGAS–STING pathway, which may contribute to impaired immunoevasion and provide a molecular basis of the previously observed DRP-104–induced antitumor immunity. Conclusions: Together, these findings reveal purinosome assembly and purine salvage as key mechanisms of cancer cell adaptation and resilience to purine shortage while identifying microtubules, MTAP, and immunoevasion deficits as therapeutic vulnerabilities.

15 October 2025
Verified
Other
Open access
JYJianpeng Yu
Jianpeng Yu
CJChen Jin
Chen Jin
CSCheng Su
Cheng Su
DMDavid Moon
David Moon
MSMichael A Sun
Michael A Sun
JHJiaoti Huang
Jiaoti Huang
Inhibiting MTAP sensitizes tumor cells to DRP-104 treatments.

15 October 2025
Verified
Other
Open access
JYJianpeng Yu
Jianpeng Yu
CJChen Jin
Chen Jin
CSCheng Su
Cheng Su
DMDavid Moon
David Moon
MSMichael A Sun
Michael A Sun
JHJiaoti Huang
Jiaoti Huang
Gene expression and functional assays implicate purine biosynthesis as a driver of prostate cancer pathogenesis.

15 October 2025
Verified
Other
Open access
JYJianpeng Yu
Jianpeng Yu
CJChen Jin
Chen Jin
CSCheng Su
Cheng Su
DMDavid Moon
David Moon
MSMichael A Sun
Michael A Sun
JHJiaoti Huang
Jiaoti Huang
Treating tumor-bearing mice with DRP-104 in combination with MTDIA does not affect animal’s body weight but alters the tumor’s immune microenvironment.

15 October 2025
Verified
Other
Open access
JYJianpeng Yu
Jianpeng Yu
CJChen Jin
Chen Jin
CSCheng Su
Cheng Su
DMDavid Moon
David Moon
MSMichael A Sun
Michael A Sun
JHJiaoti Huang
Jiaoti Huang
Prostate cancer cells develop adaptation to purine shortage inducer, such as DRP-104, and employ microtubules to assemble purinosome to enhance purine biosynthesis efficiency.

15 October 2025
Verified
Other
Open access
JYJianpeng Yu
Jianpeng Yu
CJChen Jin
Chen Jin
CSCheng Su
Cheng Su
DMDavid Moon
David Moon
MSMichael A Sun
Michael A Sun
JHJiaoti Huang
Jiaoti Huang
Purpose:Purine metabolism is a promising therapeutic target in cancer; however, how cancer cells respond to purine shortage, particularly their adaptation and vulnerabilities, remains unclear.Experimental Design:Using the recently developed purine shortage–inducing prodrug DRP-104 and genetic approaches, we investigated the responses in prostate, lung, and glioma cancer models.Results:We demonstrate that when de novo purine biosynthesis is compromised, cancer cells employ microtubules to assemble purinosomes, multiprotein complexes of de novo purine biosynthesis enzymes that enhance purine biosynthesis efficiency. Although this process enables tumor cells to adapt to purine shortage stress, it also renders them more susceptible to the microtubule-stabilizing chemotherapeutic drug docetaxel. Furthermore, we show that although cancer cells primarily rely on de novo purine biosynthesis, they also exploit methylthioadenosine phosphorylase (MTAP)–mediated purine salvage as a crucial alternative source of purine supply, especially under purine shortage stress. In support of this finding, combining DRP-104 with an MTAP inhibitor significantly enhances tumor suppression in prostate cancer models in vivo. Finally, despite the resilience of the purine supply machinery, purine shortage–stressed tumor cells exhibit increased DNA damage and activation of the cGAS–STING pathway, which may contribute to impaired immunoevasion and provide a molecular basis of the previously observed DRP-104–induced antitumor immunity.Conclusions:Together, these findings reveal purinosome assembly and purine salvage as key mechanisms of cancer cell adaptation and resilience to purine shortage while identifying microtubules, MTAP, and immunoevasion deficits as therapeutic vulnerabilities.